Clinical pharmacokinetics and pharmacodynamics of etravirine.
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityClinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected populationPharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjectsLC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studiesMarked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxisRandomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.Antimalarial pharmacology and therapeutics of atovaquoneRole of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolismUse of antineoplastic agents in patients with cancer who have HIV/AIDS.Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.Quantitative histological assessment of xenobiotic-induced liver enzyme induction and pituitary-thyroid axis stimulation in rats using whole-slide automated image analysis.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionInfluence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.Pharmacokinetic evaluation of etravirine.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Etravirine for the treatment of HIV/AIDS.Self-assembled nanoparticles made from a new PEGylated poly(aspartic acid) graft copolymer for intravaginal delivery of poorly water-soluble drugs.Pregnancy-related pharmacokinetic changes.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.Hormonal contraceptive use in HIV-infected women using antiretroviral therapy: A Systematic review.The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.Raltegravir can be used safely in HIV-1-infected patients treated with warfarin.
P2860
Q24628212-76AC8C9E-A0EA-4634-9091-E1327AFEE022Q28538921-439B12D6-6756-42AC-9A26-64E1FD372B34Q33609231-34D08C64-4B46-4BF6-8110-D15FDEB12CD8Q34233691-61E4B71A-6652-4A0F-93D7-76143C7977E5Q34306474-D699BDCC-E84C-40E5-BC28-387330826E63Q34432062-0582E961-F781-4094-B652-85D9A9DA1C7BQ35038647-E0644498-708D-4187-B568-34EA701BBD3CQ35087745-541836F1-E211-4A31-9AAC-C5D3E0DBA7CCQ35131253-A7AFCE55-568B-42F4-8746-BF122D6216B7Q35557235-1BA1B978-7D0F-49DB-9EB2-E13F42BB6CFFQ35668556-95772248-E566-493B-B710-5410E3EC88A9Q35846917-857C124D-C9D0-46BF-B131-AE8D28038412Q35932561-E77F27B8-EE51-4239-B4F0-01266E82F35DQ36279339-A8179A95-CA70-4C55-BC62-6F450E8BB15AQ36796304-E0B9CD44-247E-4C39-8EFD-5AF215A756BEQ37014157-5C3AA159-D3FF-4735-B601-9B764BB81435Q37113947-7F75DD42-2F84-47DC-B62F-2A49DF3B189BQ37150339-6DAFD197-9D4F-4265-B4D7-DBAB2CE1FD99Q37378110-DF017BCC-7162-4823-84E7-2062A61FFA59Q37639881-B11026E3-7E40-46BE-8211-B43981664F1AQ37722935-96F05A2C-6D86-40FC-9F16-20E5D38FE38CQ37809537-82D1FD06-02B0-43BC-A17B-03F07B114FD0Q37835819-4832CE66-3917-464A-B54A-66AB3FA2AF85Q37846672-588697FC-0599-4624-86A3-069752FCBEF2Q37866289-99A228CC-E5B1-47B5-9D1E-6AD743E041F1Q37866298-2D16657B-262C-455A-A9D4-7EFC15159885Q38003399-F9604600-78A2-4BB0-A4A0-F274CA7EF707Q38057372-3FD25430-400D-4304-AC1D-7AE5C37FED78Q38096459-B018443D-3B29-44AC-837F-5DBBF67B4069Q38693808-0AB4BC54-E6EE-45C5-84AE-FCD47CCC6F7DQ38809225-D86FBD0E-2FEA-4EC7-A957-CE7421841B9BQ39074109-497450A0-D166-4641-AAD9-D9F9ED97A8E5Q39353830-C440CA6F-990F-4BD5-AB9A-C21A277E385AQ40722214-BCA7B9F9-7932-4FC0-A733-7FC6E61C68ECQ41230514-5E361E0E-D3AF-4937-9F54-37CB0CE245A3Q41694386-33CD46DB-3024-4A8B-8690-71C25414DDF0Q43446224-4D048F13-FA4F-49FA-875A-519D5E07BE1CQ44257576-25B1D2CB-D56B-4C44-AEC6-AE6946BBFF92Q44394691-557A1E61-13A7-4214-BBF2-037A006E265EQ44401441-B75C39EF-3862-4E2C-8027-6F0D6A2B9C3C
P2860
Clinical pharmacokinetics and pharmacodynamics of etravirine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@en
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@nl
type
label
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@en
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@nl
prefLabel
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@en
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@nl
P2093
P1476
Clinical pharmacokinetics and pharmacodynamics of etravirine.
@en
P2093
Araz Raoof
Goedele De Smedt
Monika Schöller-Gyüre
Richard M W Hoetelmans
Thomas N Kakuda
P304
P356
10.2165/10895940-000000000-00000
P577
2009-01-01T00:00:00Z
P6179
1020544902